NRBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NRBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2024-05-13), NeuroBo Pharmaceuticals's 5-Day RSI is 81.69.
The industry rank for NeuroBo Pharmaceuticals's 5-Day RSI or its related term are showing as below:
For the Biotechnology subindustry, NeuroBo Pharmaceuticals's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, NeuroBo Pharmaceuticals's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where NeuroBo Pharmaceuticals's 5-Day RSI falls into.
The formula for calculating RSI is:
RSI | = | 100 | – | [ 100 | / | ( 1 + Average Gain | / | Average Loss )] |
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroBo Pharmaceuticals (NAS:NRBO) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.
James Patrick Tursi | director | 106 ASHLEY COURT, MOORESTOWN NJ 08057 |
Marshall H Woodworth | officer: Acting Chief Financial Officer | C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138 |
Mark A Glickman | director | C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
Joseph Hooker | officer: Interim CEO and President | C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116 |
Goldman Sachs Group Inc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
Goldman Sachs & Co. Llc | 10 percent owner | 200 WEST STREET, NEW YORK NY 10282 |
E&healthcare Investment Fund Ii | 10 percent owner | 16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211 |
E&investment, Inc. | 10 percent owner | 16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000 |
Hyung Heon Kim | director | C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000 |
Andrew I Koven | director | 3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019 |
Na Yeon Kim | director, 10 percent owner | C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115 |
Richard Kang | director | 9451 SUNNYFIELD COURT, POTOMAC MD 20854 |
D Gordon Strickland | director | C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063 |
Ben Gil Price | officer: CEO and President | 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896 |
Akash Bakshi | director, officer: SVP and COO | 602 BAINBRIDGE STREET, FOSTER CITY CA 94404 |
From GuruFocus
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire • 12-28-2023
By PRNewswire • 10-17-2023
By PRNewswire PRNewswire • 06-13-2023
By PRNewswire • 08-14-2023
By PRNewswire PRNewswire • 11-04-2022
By PRNewswire • 08-09-2023
By PRNewswire PRNewswire • 05-06-2022
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire PRNewswire • 06-15-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.